11 Jun 2019
Melvyn’s story
In 2012 Melvyn, a bone marrow transplant patient, suffering from an aggressive form of graft-versus-host-disease was given pioneering, life-saving treatment, Mesenchymal Stem Cell Therapy, at The Catherine Lewis Centre.
“I was first diagnosed with leukaemia in July 1998 after complaining of fatigue to my local GP,” says Melvyn.
“I didn’t know what the disease was at the time but my wife Pauline took the news very badly as she understood what the outcome could be.
“I wanted to see my children graduate – my daughter was 13 and my son 15 – so I was determined to fight it and stay positive. It was a huge shock for my family.”
Melvyn successfully underwent a stem cell transplant just 10 weeks later, and although he responded well initially he started to experience a serious complication called graft-versus-host-disease (GvHD), where the newly transplanted cells attack the recipient’s body.
“I remember reaching out to turn the bedside lamp off and noticing for the first time hard lumps on my arms. By the time I went to clinic, it had spread all over my body from my neck to my ankles and my skin had become so thick that I found it hard to move.
“I saw the rheumatologist and started a new steroid drug regime, it worked well for around two years, but the risk of infection and relapse were so high that I stopped taking them.
“After a couple of years GvHD deteriorated; but thankfully, because of research funded by Leukaemia UK, I was given the opportunity to trial a new treatment called Mesenchymal Stem Cell Therapy, which has significantly improved my life.”
Professor Francesco Dazzi
“Leukaemia UK has enabled us to initiate this treatment and gather preliminary evidence with some extraordinary results. In Melvyn’s case, we isolated cells taken from his daughter, prepared them here at The Catherine Lewis Centre and, when they were ready, we infused them.
“We have seen a 50% improvement in Melvyn’s condition and I am thrilled that we have been able to improve both his outlook and quality of life.”
Related posts
4 April 2022
Leukaemia UK launches search for five new talented Trustees
We are looking for a talented and diverse set of Trustees to join our Board, and help guide the charity as we embark on an ambitious new strategy to accelerate progress in leukaemia research to stop leukaemia devastating lives.
1 August 2022
A research breakthrough targets cancer over healthy tissue, bringing possibility of a new treatment option for most deadly type of leukaemia
A new scientific paper published on 22nd June in Science Translational Medicine, announced a breakthrough by Leukaemia UK-funded scientist Dr William Grey that could lead to a vital new treatment option for…
16 November 2021
John Goldman Fellowships for 2022 open in December
Leukaemia UK is delighted to continue its investment and funding for early career scientists and clinicians in 2022.
4 July 2022
Cancer charities unite in encouraging the Government to address crucial issues as part of their “War on Cancer”
In collaboration with our partners and as part of the One Cancer Voice group, Cancer 52 and Blood Cancer Alliance, we have called on the Government to take account of a wide range of recommendations as they finalise the 10-Year Cancer Plan to be announced later this year.